secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001213900-25-119898
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix
--------------------------------------------------------------------------------

- Proteomedix (wholly owned by Onconetix) amended license with Labcorp for a new validation study of Proclarix (PRIME Study).
- Onconetix will pay Labcorp milestone-based payments up to $300,000 total and bear all study costs.
- Mid-five-figure payments per enrolled subject batch; fixed per-subject fee if final milestone not met.
- Labcorp not required to pay royalties or milestones for use of the risk calculator in this PRIME Study.
- Labcorp must provide study results to Onconetix but Onconetix cannot use or disclose without Labcorp's consent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025119898/0001213900-25-119898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025119898/ea0269052-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-119898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer